Skip to main content

Table 4 Types of testing used for different programmes

From: Values, preferences and current hepatitis B and C testing practices in low- and middle-income countries: results of a survey of end users and implementers

Targeted population

Number of LMIC (% of LMIC)*

HBV testing

HCV testing

RDT/EIA/RIA

DNA

FS

RDT/EIA/RIA

RNA

cAg

FS

Blood donors

18 (90%)

5 (25%)

0

19 (86.4%)

5 (22.7%)

0

1 (4.5%)

Health-care workers

12 (60%)

3 (15%)

0

10 (45.5%)

1 (4.5%)

0

0

People who inject drugs

9 (45%)

3 (15%)

0

11 (50%)

1 (4.5%)

0

1 (4.5%)

Men who have sex with men

8 (40%)

1 (5%)

0

6 (27.3%)

0

0

0

Migrants

0

0

0

1 (4.5%)

0

0

0

Pregnant women

15 (75%)

2 (10%)

0

7 (31.8%)

1 (4.5%)

0

0

Children born to HCV/HBV-infected mothers

14 (70%)

4 (20%)

0

12 (54.5%)

3 (13.6%)

0

1 (4.5%)

Chronically ill

6 (30%)

1 (5%)

0

7 (31.8%)

0

0

0

Commercial sex workers

8 (40%)

1 (5%)

0

3 (13.6%)

0

0

0

People living with HIV

12 (60%)

6 (30%)

1 (5%)

9 (40.9%)

1 (4.5%)

0

1 (4.5%)

Prisoners

4 (20%)

1 (5%)

1 (5%)

5 (22.7%)

1 (4.5%)

0

1 (4.5%)

Population-wide testing

4 (20%)

1 (5%)

1 (5%)

2 (9.1%)

0

0

0

Testing is not a part of any programme

1 (5%)

0

0

1 (4.5%)

1 (4.5%)

0

1 (4.5%)

Other

1 (5%)

1 (5%)

1 (5%)

1 (4.5%)

0

0

0

Total

20

22

  1. *number and per cent of LMIC refer to LMIC represented in the survey responses
  2. RDT/EIA/RIA – rapid diagnostic test/enzyme immunoassay/radioimmunoassay; DNA – HBV DNA test; RNA – HCV RNA test; cAg – HCV core antigen test; FS – Fibrosis staging